The commercial AI market is no longer speculative. OpenAI has crossed $25 billion in annualized revenue, and is reportedly taking early steps toward a public listing, potentially as soon as late 2026. Crescendo AI At the same time, its main rival is keeping pace in a way that would have seemed impossible 18 months ago.
Anthropic has reportedly flipped from money-loser to revenue powerhouse in just a few months. Annualized revenue now tops $30 billion, possibly edging out OpenAI. LLM Leaderboard
Two years ago, neither company was generating revenue at this scale. The speed of the commercial ramp is extraordinary.
What's Driving Anthropic's Revenue
Anthropic's momentum is fueled by explosive growth, with the company's annual run-rate revenue skyrocketing to $30 billion in April 2026, driven largely by enterprise adoption and the success of Claude Code. VentureBeat
Claude Code's traction with engineering teams has been the standout. Enterprise customers deploying AI for software development are generating high-volume API usage - exactly the revenue model that compounds quickly.
The IPO Signal
OpenAI's reported steps toward a public listing represent a significant moment for the AI industry. Going public would require unprecedented transparency about unit economics, margins, and compute costs - information the company has never disclosed publicly. It would also give retail investors direct access to AI's most prominent brand.
The timing makes sense: revenue is real, growth is explosive, and the window of market enthusiasm for AI companies is open. The risk is that public market scrutiny could expose how capital-intensive the underlying business actually is.
What This Means for Your Business
For executives tracking AI vendor stability and long-term partnership risk, these revenue figures change the calculus. OpenAI and Anthropic are no longer venture-funded experiments - they are genuine enterprise software businesses with the revenue to sustain multi-year roadmaps. That makes enterprise commitments to either platform less risky than they were even 12 months ago.
